Related Experiment Videos
E2F proteins regulate MYCN expression in neuroblastomas.
1Institute of Molecular Biology and Tumor Research (IMT), Emil-Mannkopff-Strasse 2, 35033 Marburg, Germany.
The Journal of Biological Chemistry
|November 20, 2002
Summary
Transcription factors E2F-1, E2F-2, and E2F-3 activate MYCN expression in neuroblastoma, a cancer with poor prognosis. These E2F proteins are critical for regulating MYCN gene activity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MYCN gene amplification is a hallmark of aggressive neuroblastomas.
- The specific transcription factors that regulate MYCN expression in neuroblastoma remain unidentified.
Purpose of the Study:
- To identify the transcription factors responsible for driving MYCN expression in neuroblastoma.
- To investigate the role of E2F transcription factors in MYCN regulation.
Main Methods:
- Transient-transfection assays to assess MYCN reporter activation by E2F proteins.
- Chromatin immunoprecipitation (ChIP) to detect E2F binding to the MYCN promoter in vivo.
- Overexpression of p16(INK4A) to inhibit E2F activity and measure MYCN expression levels.
Main Results:
- E2F-1, E2F-2, and E2F-3 were found to activate a MYCN reporter construct.
- E2F proteins bind to the MYCN promoter in neuroblastoma cell lines with MYCN amplification.
- Inhibition of E2F activity reduced MYCN expression, and E2F proteins are implicated in TGF-beta and retinoic acid-mediated repression of MYCN.
Conclusions:
- E2F transcription factors are crucial for the activation of MYCN in neuroblastoma.
- E2F proteins play a significant role in both the activation and repression of MYCN expression.
- Targeting E2F activity may offer a therapeutic strategy for MYCN-driven neuroblastomas.